Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 10/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25624590 | 0.96 | ALOX5 (0.43) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL25624613 | 0.96 | ALOX5 (0.43) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL25624550 | 0.96 | ALOX5 (0.43) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL19770483 | 0.95 | ALOX5 (0.46) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL25624509 | 0.94 | ALOX5 (0.46) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL25624543 | 0.91 | ALOX5 (0.48) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL25624581 | 0.90 | CA12 (0.41) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL22707211 | 0.90 | ALOX5 (0.46) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL10442466 | 0.90 | ALOX5 (0.57) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL10442588 | 0.90 | ALOX5 (0.57) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371376-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | SFC CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230371376-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | SFC CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371376-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | PPOX, MAP1LC3A, VDAC2 | ALOX5 870/4885PRKDC 2818/4885PLA2G2A 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.